依诺肝素与阿司匹林在骨科创伤患者血栓预防中的成本效果比较
该研究从美国医疗系统角度,基于近期临床试验数据构建决策分析模型,比较依诺肝素30 mg与阿司匹林81 mg(每日两次,住院期间及出院后21天)在成人手术治疗的四肢、骨盆或髋臼骨折患者中的成本效果。模型估计依诺肝素1年医疗成本为35,301美元、产生0.6705 QALYs,阿司匹林为35,067美元、0.6701 QALYs,增量成本效果比为每QALY 635,340美元,提示依诺肝素相对阿司匹林不具有成本效果。
要点
- 依诺肝素较阿司匹林1年医疗成本高234美元,QALYs仅改善0.0004。
- 依诺肝素增量成本效果比为每QALY 635,340美元,超过意愿支付阈值150,000美元/QALY。
- 敏感性分析中依诺肝素具有成本效果的概率在10,000次迭代中为9.8%。
核心结论
- 研究结果表明,在骨科创伤患者血栓预防中,依诺肝素相对阿司匹林不具有成本效果。
- 作者认为结果支持在未来指南中考虑将阿司匹林作为首选药物,尤其考虑到患者对其口服给药的一贯偏好。
研究设计与样本
- 成本效果研究,基于近期临床试验和国家数据库数据,模拟成人手术治疗的四肢、骨盆或髋臼骨折患者假设队列。
- 采用决策分析模型比较依诺肝素30 mg与阿司匹林81 mg,每日两次住院期间给药,出院后处方21天。
- 从美国医疗系统角度,基于潜在疾病状态(死亡或肺栓塞、近端深静脉血栓、远端深静脉血栓或出血并发症的组合)计算1年内医疗成本和质量调整生命年(QALYs)。
- 以每QALY 150,000美元的意愿支付阈值评估成本效果。
- 证据等级:经济与决策分析Level I。
主要发现
- 依诺肝素组1年医疗成本为35,301美元,产生0.6705 QALYs。
- 阿司匹林组1年医疗成本为35,067美元,产生0.6701 QALYs。
- 依诺肝素较阿司匹林总体医疗成本高234美元,QALYs仅改善0.0004,增量成本效果比为每QALY 635,340美元。
- 敏感性分析中,10,000次迭代下依诺肝素血栓预防具有成本效果的概率为9.8%。
关键数值与推荐
- 依诺肝素30 mg每日两次住院期间给药,出院后处方21天;阿司匹林81 mg每日两次住院期间给药,出院后处方21天。
- 意愿支付阈值为每QALY 150,000美元。
- 依诺肝素增量成本效果比为每QALY 635,340美元,提示依诺肝素相对阿司匹林不具有成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although clinical guidelines endorse enoxaparin for the prevention of venous thromboembolism in patients with orthopaedic trauma, recent evidence from a large clinical trial has demonstrated that aspirin provides comparable protection against death and pulmonary embolism. This study evaluated the cost-effectiveness of thromboprophylaxis with enoxaparin compared with that with aspirin in patients with orthopaedic trauma from the perspective of the U.S. health-care system. METHODS: The study modeled a hypothetical cohort of adult patients with an operatively treated extremity, pelvic, or acetabular fracture based on data from a recent clinical trial and national databases. We used a decision analysis model to compare 30 mg of enoxaparin with 81 mg of aspirin, administered twice daily in-hospital and prescribed for 21 days after discharge. Health-care costs and quality-adjusted life-years (QALYs) within 1 year after the injury derived from published research and publicly available cost data were based on potential disease states, including death or a combination of pulmonary embolism, proximal deep vein thrombosis, distal deep vein thrombosis, or a bleeding complication. We assessed cost-effectiveness compared with a willingness-to-pay threshold of $150,000 per QALY. RESULTS: Our model estimated that the 1-year health-care costs among patients prescribed enoxaparin were $35,301, producing 0.6705 QALYs. Aspirin was associated with $35,067 in 1-year health-care costs and 0.6701 QALYs. The overall health-care costs were $234 higher with enoxaparin but yielded only a 0.0004 improvement in QALYs, for an incremental cost-effectiveness ratio for enoxaparin of $635,340 per QALY, indicating that enoxaparin is not cost-effective compared with aspirin. In a sensitivity analysis, the probability of enoxaparin thromboprophylaxis being cost-effective compared with aspirin was 9.8% in 10,000 iterations. CONCLUSIONS: The findings suggest that enoxaparin is not cost-effective relative to aspirin for thromboprophylaxis in patients with orthopaedic trauma. The results support consideration of aspirin as a preferred agent in future guidelines, especially given the consistent patient preference for its oral administration. LEVEL OF EVIDENCE: Economic and Decision Analysis Level I . See Instructions for Authors for a complete description of levels of evidence.
引用
- Levy JF, O'Toole RV, Stein DM, et al. The Cost-Effectiveness of Enoxaparin Compared with Aspirin for Thromboprophylaxis in Patients with Orthopaedic Trauma. J Bone Joint Surg Am. 2026. PMID: 41587264. doi:10.2106/JBJS.25.00681
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。